Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARLIGHT: Psilocybin-Assisted Therapy for PTSD in Veterans
NCT06888128Phase 2Recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in post-traumatic stress disorder (PTSD), sponsored by Baylor College of Medicine. Primary endpoints: Safety of psilocybin-assisted therapy for PTSD at 6 months and Efficacy of psilocybin-assisted therapy for PTSD at 6 months. Started Jan 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT06888128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888128.